The (−765 G→C) promoter variant of the COX-2/PTGS2 gene is associated with a lower risk for end-stage hip and knee osteoarthritis
- 1Division for Experimental Anaesthesiology, Department of Anaesthesiology, University Hospital Ulm, Ulm, Germany
- 2Division for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University Hospital Ulm, Ulm, Germany
- 3Institute of Human Genetics, University of Ulm, Ulm, Germany
- 4Department of Orthopedic Surgery, University Hospital Dresden, Dresden, Germany
- 5Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
- Correspondence to Professor Dr R E Brenner, Division for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University Hospital Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany; rolf.brenner{at}uni-ulm.de
- Accepted 31 January 2010
- Published Online First 8 April 2010
Abstract
Background Functional polymorphisms in genes of proinflammatory signalling cascades may contribute to the genetic risk of osteoarthritis (OA).
Objective To examine a possible association between end-stage OA of the hip and knee joint and a known single nucleotide polymorphism (SNP) of the COX-2 gene promoter.
Methods The SNP −765 G→C (rs20417) of the COX-2 gene promoter was genotyped by pyrosequencing in 531 (320 women/211 men) patients with OA from the Ulm Osteoarthritis Study and 400 (200 women/200 men) regional controls from the south-west of Germany.
Results In the whole study population the C allele was associated with a lower risk (per allele OR 0.57; 95% CI 0.43 to 0.75, p<0.0001) and the G allele with a higher risk for end-stage OA. Analysis of subgroups confirmed this result for primary, bilateral, hip and knee OA.
Conclusion The promoter polymorphism rs20417 of the COX-2 gene contributes to the genetic risk for end-stage hip and knee OA.
Footnotes
-
Competing interests None.
-
Ethics approval This study was conducted with the approval of the Local Ethics Committee of the University of Ulm, Germany, and the consent of the patients.
-
Provenance and peer review Not commissioned; externally peer reviewed.








